Remegen

company

About

Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.

  • 11 - 50

Details

Last Funding Type
Private Equity(PE)
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
11 - 50
Operating Status
Active

RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$100M
Remegen has raised a total of $100M in funding over 2 rounds. Their latest funding was raised on Mar 17, 2020 from a Private Equity(PE) round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 17, 2020 Private Equity(PE) $100M 1 Lilly Asia Ventures — Detail
Dec 7, 2019 Private Equity(PE) — 2 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Remegen is funded by 3 investors. Lilly Asia Ventures and Huatai Health Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures Yes Private Equity(PE)
Huatai Health Fund — Private Equity(PE)
Mingxin China Growth Fund — Private Equity(PE)